G1 Therapeutics, Inc.
GTHX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.36 | -0.08 | 0.35 |
| FCF Yield | -24.30% | -54.51% | -30.85% | -12.29% |
| EV / EBITDA | -4.68 | -1.68 | -2.04 | -5.26 |
| Quality | ||||
| ROIC | -46.04% | -89.74% | -62.98% | -47.71% |
| Gross Margin | 91.28% | 92.69% | 93.60% | 100.00% |
| Cash Conversion Ratio | 0.80 | 0.87 | 0.89 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 37.88% | 4.25% | – | – |
| Free Cash Flow Growth | 70.31% | 2.26% | -57.76% | 18.13% |
| Safety | ||||
| Net Debt / EBITDA | -0.64 | 0.08 | 0.97 | 1.88 |
| Interest Coverage | -3.94 | -13.05 | -30.52 | -54.26 |
| Efficiency | ||||
| Inventory Turnover | 0.58 | 0.23 | 0.58 | 0.00 |
| Cash Conversion Cycle | 484.79 | 930.86 | 169.88 | 1.91 |